Amyris Stock News

EMERYVILLE, Calif., Nov. 23, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market operating platform, today announced that

Amyris' stock dropped sharply after a big miss in Q3 and the announcement of a convertible offering. We think it's a buying opportunity. Read more to know why.

Big Revenue miss for Q3 due to supply chain shortages and Amyris guides lower for Q4. Surprise $690 million convert is less dilutive (12%, not 18%) and at a beneficially higher effective conversion pr

Origin Materials (OTCMKTS:ORGN) and Amyris (NASDAQ:AMRS) are both oils/energy companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations. Profitability This table compares Origin Materials and Amyris net margins, return on equity and return on assets. []

Related Stocks: BYSI , NXE , AMRS , CG , MO , CCJ ,

Amyris' synthetic biotechnology breakthrough with squalene. The real crown jewel of Amyris' current business segment.

There's nothing artificial about the plunging price of this synthetic biology stock.

Bears are turning their backs on this synbio stock today.

The stock price of Amyris Inc (NASDAQ: AMRS) fell over 30% during intraday trading today. This is why it happened.

Amyris, Inc. (AMRS) CEO John Melo on Q3 2021 Results - Earnings Call Transcript

Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19 vaccine. The parties have signed a binding te

Amyris: Assessing Financial Capacity To Sustain Organic Growth, Carry COVID Research And Pay For Acquisition

The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it.